Back
Science

U.S. Cancer Survival Rate Reaches 70%, Driven by Treatment Advances and Early Detection

Generated on: Last updated: 2 sources
View source

U.S. Achieves 70% Five-Year Cancer Survival Rate Amidst Ongoing Challenges

The United States has achieved a 70% five-year cancer survival rate for all cancers combined, according to reports from the American Cancer Society (ACS). This figure, based on diagnoses from 2015 to 2021, represents a notable increase from 50% in the 1970s and 63% in the mid-1990s. Advances in treatment options and early detection methods are cited as primary factors contributing to this positive trend.

National Survival Trends

Approximately 7 out of 10 cancer patients live five years or more after diagnosis.

The five-year survival benchmark is a standard measure in oncology, as the risk of recurrence for many cancers significantly diminishes after this period. The ACS's 75th annual Cancer Statistics report details that five-year survival rates have risen by an average of 20% over the last five decades.

Overall, the cancer death rate has decreased by 34% since its peak in 1991, contributing to an estimated 4.8 million cancer deaths prevented as of 2023. This reduction is attributed to improved treatments, earlier detection, and decreased smoking rates.

Survival prospects for later-stage diagnoses have also shown improvement, with the average five-year survival rate for cancers that had spread to distant organs increasing from 17% in the mid-1990s to 35% in the 2020s.

Advances in Treatment and Early Detection

Improved understanding of cancer development has led to the development of more effective treatments. Key advancements include:

  • Immunotherapies: These treatments enhance the immune system's ability to identify and attack cancer cells.
  • Targeted Therapies: These therapies focus on specific genes or proteins that drive cancer cell growth, often resulting in fewer side effects and less damage to healthy tissue.
  • Specific Modalities: Immune checkpoint therapy, CAR T-cell therapy, and tyrosine kinase inhibitors have been instrumental in improving patient outcomes.

These treatment innovations, alongside routine screening practices leading to earlier diagnoses, have contributed to increased survival rates across various cancer types:

  • Myeloma: The five-year survival rate for this blood cancer has doubled from 32% in the mid-1990s to 62%.
  • Lung Cancer: Regional lung cancer survival has risen from 20% to 37% since the mid-1990s, while the overall lung cancer rate has increased from 15% to 28%.
  • Pancreatic Cancer: For the first time, its five-year survival rate has exceeded 10%, reaching 13% over the last two decades.
  • Liver Cancer: The relative survival rate increased from 7% in the 1990s to 22% in 2023.
  • Leukemia: Saw a 20% increase in five-year survival.
  • Non-Hodgkin Lymphoma: Experienced an 18% increase.
  • Ovarian Cancer: Noted a 9% increase.

High five-year survival rates are also reported for specific cancers, including 92% for breast cancer in women, 95% for melanoma of the skin, and 98% for prostate cancer.

Persistent Challenges and Concerns

Despite the progress, challenges persist in cancer care and prevention:

  • Rising Cancer Rates: The national obesity epidemic is identified as a contributing factor to increasing rates of certain cancers, such as colorectal cancer in individuals under 50 and overall breast cancer rates among women.
  • Projected Burden: The American Cancer Society projects over 2.1 million new cancer diagnoses and more than 626,000 cancer deaths in the U.S. this year.
  • Research Funding: Concerns have been raised regarding potential reductions in cancer research funding. An analysis by Senate Democrats indicated a 31% decline in cancer research grant funding for the first three months of 2025 compared to the same period in 2024.
  • Disparities in Care: Disparities in cancer burden continue to affect communities of color, particularly Native American and Black populations. The expiration of Affordable Care Act insurance subsidies may also limit access to crucial cancer treatments for these groups.
  • COVID-19 Impact: Disruptions to cancer screening during the COVID-19 pandemic could lead to an increase in late-stage diagnoses, with the full extent of this impact yet to be observed.